HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 282, Issue 43, 31186-31196, October 26, 2007

This Article Full Text Full Text (PDF) All Versions of this Article: 282/43/31186    most recent M704935200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dicker, I. B. Articles by Krystal, M. Search for Related Content PubMed PubMed Citation Articles by Dicker, I. B. Articles by Krystal, M. Social Bookmarking                      What's this?

Changes to the HIV Long Terminal Repeat and to HIV Integrase Differentially Impact HIV Integrase Assembly, Activity, and the Binding of Strand Transfer Inhibitors^*

Ira B. Dicker¹, Himadri K. Samanta, Zhufang Li, Yang Hong, Yuan Tian, Jacques Banville^¶, Roger R. Remillard^¶, Michael A. Walker^¶, David R. Langley^||, and Mark Krystal

From the Departments of Virology, ^¶Medicinal Chemistry, and ^||Computer Assisted Drug Design, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492 and the Radiochemistry Group, Department of Chemical Synthesis, Pharmaceutical Research Institute, Princeton, New Jersey 08540

Human immunodeficiency virus (HIV) integrase enzyme is required for the integration of viral DNA into the host cell chromosome. Integrase complex assembly and subsequent strand transfer catalysis are mediated by specific interactions between integrase and bases at the end of the viral long terminal repeat (LTR). The strand transfer reaction can be blocked by the action of small molecule inhibitors, thought to bind in the vicinity of the viral LTR termini. This study examines the contributions of the terminal four bases of the nonprocessed strand (G²T¹C^–1A^–2) of the HIV LTR on complex assembly, specific strand transfer activity, and inhibitor binding. Base substitutions and abasic replacements at the LTR terminus provided a means to probe the importance of each nucleotide on the different functions. An approach is described wherein the specific strand transfer activity for each integrase/LTR variant is derived by normalizing strand transfer activity to the concentration of active sites. The key findings of this study are as follows. 1) The G²:C² base pair is necessary for efficient assembly of the complex and for maintenance of an active site architecture, which has high affinity for strand transfer inhibitors. 2) Inhibitor-resistant enzymes exhibit greatly increased sensitivity to LTR changes. 3) The strand transfer and inhibitor binding defects of a Q148R mutant are due to a decreased affinity of the complex for magnesium. 4) Gln¹⁴⁸ interacts with G², T¹, and C^–1 at the 5' end of the viral LTR, with these four determinants playing important and overlapping roles in assembly, strand transfer catalysis and high affinity inhibitor binding.

Received for publication, June 14, 2007 , and in revised form, August 20, 2007.

^* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom correspondence should be addressed: Bristol-Myers Squibb Co., 5 Research Pkwy., Wallingford, CT 06492. Tel.: 203-677-7736; Fax: 203-677-6088; E-mail: Ira.Dicker{at}BMS.com.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Alian, S. L. Griner, V. Chiang, M. Tsiang, G. Jones, G. Birkus, R. Geleziunas, A. D. Leavitt, and R. M. Stroud Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs PNAS, May 19, 2009; 106(20): 8192 - 8197. [Abstract] [Full Text] [PDF]

				O. Goethals, R. Clayton, M. Van Ginderen, I. Vereycken, E. Wagemans, P. Geluykens, K. Dockx, R. Strijbos, V. Smits, A. Vos, et al. Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors J. Virol., November 1, 2008; 82(21): 10366 - 10374. [Abstract] [Full Text] [PDF]

				O. Delelis, K. Carayon, E. Guiot, H. Leh, P. Tauc, J.-C. Brochon, J.-F. Mouscadet, and E. Deprez Insight into the Integrase-DNA Recognition Mechanism: A SPECIFIC DNA-BINDING MODE REVEALED BY AN ENZYMATICALLY LABELED INTEGRASE J. Biol. Chem., October 10, 2008; 283(41): 27838 - 27849. [Abstract] [Full Text] [PDF]

				I. B. Dicker, B. Terry, Z. Lin, Z. Li, S. Bollini, H. K. Samanta, V. Gali, M. A. Walker, and M. R. Krystal Biochemical Analysis of HIV-1 Integrase Variants Resistant to Strand Transfer Inhibitors J. Biol. Chem., August 29, 2008; 283(35): 23599 - 23609. [Abstract] [Full Text] [PDF]